Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (689)	7/30/1998 3:15:00 AM
From: Richard Huth	Read Replies (1) \| Respond to of 3202

This discussion about XOMA is very interesting, but (plaese be patient with me) I think completely unnecessary. I assume that we all believe that Incyte has not lost anything with the deal (as rocketman described excellent), but has the opportunity to win a lot. But we are not going to see any price reaction nearterm, whatever might be the outcome of BPI or any other revenue stream from royalties or warrants. Talking as a European investor, most US investors do not look longterm, even in biotech. Especially if a company is already in the black - for example, PER is commonly based on actual earnings, not on earnings expected one and two years in front. And this will limit the price impact of any deal with revenue streams 4-6 years in future. And this is the reason why Incyte is seen as "cheap" by some investors. If the bulk is looking only till 2000, they will miss a big portion of coming profits. But would it help us if Incyte would be acquired by a big pharma at this price levels, because they think this might be good bargain, too? Even if they are paying a nice premium, wouldn't we loose a lot? Let's assume they pay 45, what could Incyte be traded in 2003? In this case I prefer to stay long in an undervalued stock with an excellent longterm outlook, instead of pocketing a quick premium. Richard

To: Bluegreen who wrote (689)	7/30/1998 10:23:00 AM
From: rkrw	Read Replies (1) \| Respond to of 3202

Bluegreen, This helps people make money in risky biotechs in many ways. The differences in management and capability between XOMA and INCY is about as broad as you get. Whereas INCY has had a keen eye on shareholder value and dilution for its entire existence, XOMA has dropped the ball countless times and has treated shareholders as nothing more than a financing tool. This difference in philosophy has shown itself in the putrid returns of XOMA and returns among the best of all of biotech for INCY. To take it a step further, XOMA has screwed shareholders again and again, whereas INCY has conceived and executed a brilliant business plan that is now being emulated by others. I would not call INCY a risky biotech investment by any standard. Obviously you believe that the tide has turned and XOMA is headed in the right direction. That has yet to be shown.